Free Trial
→ Undiscovered Sub-$1 Gold-Silver Royalty Stock Takes Flight (From Digest Publishing) (Ad)tc pixel
OTCMKTS:ZLDPF

Zealand Pharma A/S Q3 2025 Earnings Results & Report

Zealand Pharma A/S logo
$34.00 0.00 (0.00%)
As of 10/15/2026 10:37 AM Eastern

Zealand Pharma A/S beat analyst expectations on both earnings and revenue in its Q3 2025 results, released November 13, 2025. The company reported EPS of -$0.90 versus the -$1.11 consensus estimate, while revenue of $7.76 million topped the $4.54 million estimate by $3.22 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens

Zealand Pharma A/S EPS Results

Actual EPS
-$0.90
Consensus EPS
-$1.11
Beat/Miss
Beat by +$0.21
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Zealand Pharma A/S Revenue Results

Actual Revenue
$7.76 million
Expected Revenue
$4.54 million
Beat/Miss
Beat by +$3.22 million
YoY Revenue Growth
N/A

Upcoming Earnings

Zealand Pharma A/S' next earnings date is estimated for Thursday, November 12, 2026, based on past reporting schedules.

Conference Call Resources

Zealand Pharma A/S Q3 2025 Earnings FAQ

Zealand Pharma A/S (OTCMKTS:ZLDPF) reported earnings of -$0.90 per share for Q3 2025, beating the consensus estimate of -$1.11. The report was announced on Thursday, November 13, 2025.

Zealand Pharma A/S reported revenue of $7.76 million for Q3 2025, against a consensus estimate of $4.54 million.

Zealand Pharma A/S' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Zealand Pharma A/S on the company's earnings history page.

Zealand Pharma A/S Earnings Headlines

Zealand Pharma A/S (OTCMKTS:ZLDPF) Sets New 52-Week Low - Time to Sell?
October 16 at 3:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31124784
Zealand Pharma A/S (OTCMKTS:ZLDPF) Hits New 1-Year Low - Time to Sell?
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31105403
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congressmen no cameras, no staff. What he found afterward points to a coordinated Two-Front Economic War already in motion, according to his research at Behind the Markets.tc pixel
October 16 at 1:00 AM  |  Behind the Markets (Ad)
Zealand, Roche release phase 2 topline data for amylin analogue petrelintide
October 8, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/zealand-roche-release-phase-2-topline-data-for-amylin-analogue-petrelintide/ar-AA2dRaYy
Petrelintide Phase III Trial Puts Zealand Pharma in the Obesity–Heart Disease Spotlight
October 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/petrelintide-phase-iii-trial-puts-zealand-pharma-in-the-obesity-heart-disease-spotlight?utm_source=marketbeat.com&utm_medium=referral
Zealand Pharma Advances Petrelintide Into Phase III, Raising Its Profile in the Obesity Drug Race
October 7, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zealand-pharma-advances-petrelintide-into-phase-iii-raising-its-profile-in-the-obesity-drug-race?utm_source=marketbeat.com&utm_medium=referral
See More Zealand Pharma A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zealand Pharma A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zealand Pharma A/S and other key companies, straight to your email.

About Zealand Pharma A/S

Zealand Pharma A/S (OTCMKTS:ZLDPF) is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes. The company has also developed several investigational medicines, including petrelintide, an amylin analog being studied for weight management, and other peptide-based candidates for metabolic and gastrointestinal conditions. Zealand previously discovered lixisenatide, which was developed and commercialized through a collaboration with Sanofi under the names Adlyxin and Lyxumia.

Founded in 1998, Zealand Pharma serves international markets through its own activities and collaborations with pharmaceutical partners. Its development programs have included partnerships with companies such as Boehringer Ingelheim, particularly in obesity and related metabolic diseases. Zealand is led by President and Chief Executive Officer Adam Steensberg and is headquartered in Søborg, Denmark.

View Zealand Pharma A/S Profile
Earnings Tools